Summary of duties

Jiyang is a leading biomedical company in China, specializing in the development and production of new drugs for the treatment of cancer and autoimmune diseases and biological analogs. Through the efficient R & D system and the production capacity of low-cost products, Marketplace is committed to providing high-volume and affordable new biological products in the market, and to make full use of its rich R & D experience to develop a variety of treatment products. The waiting product line of the collection currently includes 9 single clone antibodies, of which 3 are the core products of III: CMAB007, CMAB009 and CMAB008. In addition, other candidate options CMAB809 and CMAB819 have been approved for bed screening.

Thank you very much.

Note that there is a huge demand and growth of cancer and autoimmune diseases in China.

Strengthen the ability of R & D to form a multi-scale and comprehensive R & D line of single clone resistance.

Single clone antibody is the first in the field of manufacturing technology, the production base is efficient, and it has obvious cost savings.

Negative factor

Since its establishment, it has not generated income and accumulated significant income, and it is estimated that it will continue to generate revenue in the future and may never make or maintain a profit. If the company fails to successfully complete the bed development, obtain regulatory approval and commercialize its candidates, or if such events are subject to significant delays, all or part of the investment may be lost.

Pre-bed and bed development involves a long and expensive process, and the results of research and development cannot be determined.

In the process of the discovery, development and manufacture of biological products, we are responsible for the discovery, development and manufacture of biological products, especially the products.

The purpose of the income

About 70.1% is used for R & D activities of core products, expenditure related to large-scale production and other expenses, as well as in Taizhou.

Expenditure on capital related to the construction of new students

About 20.1% is used for R & D activities of other waiting products.

About 9.8% is used for general financial assistance.